首页> 外文期刊>The Lancet >High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial.
【24h】

High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial.

机译:高剂量维生素D(3)在肺结核强化期抗微生物治疗期间:一项双盲随机对照试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Vitamin D was used to treat tuberculosis in the pre-antibiotic era, and its metabolites induce antimycobacterial immunity in vitro. Clinical trials investigating the effect of adjunctive vitamin D on sputum culture conversion are absent. METHODS: We undertook a multicentre randomised controlled trial of adjunctive vitamin D in adults with sputum smear-positive pulmonary tuberculosis in London, UK. 146 patients were allocated to receive 2.5 mg vitamin D(3) or placebo at baseline and 14, 28, and 42 days after starting standard tuberculosis treatment. The primary endpoint was time from initiation of antimicrobial treatment to sputum culture conversion. Patients were genotyped for TaqI and FokI polymorphisms of the vitamin D receptor, and interaction analyses were done to assess the influence of the vitamin D receptor genotype on response to vitamin D(3). This trial is registered with ClinicalTrials.gov number NCT00419068. FINDINGS: 126 patients were included in the primary efficacy analysis (62 assigned to intervention, 64 assigned to placebo). Median time to sputum culture conversion was 36.0 days in the intervention group and 43.5 days in the placebo group (adjusted hazard ratio 1.39, 95% CI 0.90-2.16; p=0.14). TaqI genotype modified the effect of vitamin D supplementation on time to sputum culture conversion (p(interaction)=0.03), with enhanced response seen only in patients with the tt genotype (8.09, 95% CI 1.36-48.01; p=0.02). FokI genotype did not modify the effect of vitamin D supplementation (p(interaction)=0.85). Mean serum 25-hydroxyvitamin D concentration at 56 days was 101.4 nmol/L in the intervention group and 22.8 nmol/L in the placebo group (95% CI for difference 68.6-88.2; p<0.0001). INTERPRETATION: Administration of four doses of 2.5 mg vitamin D(3) increased serum 25-hydroxyvitamin D concentrations in patients receiving intensive-phase treatment for pulmonary tuberculosis. Vitamin D did not significantly affect time to sputum culture conversion in the whole study population, but it did significantly hasten sputum culture conversion in participants with the tt genotype of the TaqI vitamin D receptor polymorphism. FUNDING: British Lung Foundation.
机译:背景:维生素D在抗生素时代之前曾被用于治疗结核病,其代谢产物在体外可诱导抗分枝杆菌免疫。缺乏临床研究补充维生素D对痰培养物转化的影响。方法:我们在英国伦敦对痰涂片阳性的肺结核成人进行了辅助维生素D的多中心随机对照试验。 146名患者被分配在开始标准结核病治疗后以及基线,第14、28和42天接受2.5 mg维生素D(3)或安慰剂。主要终点是从开始抗菌治疗到痰培养转化的时间。对患者的维生素D受体TaqI和FokI基因多态性进行了基因分型,并进行了相互作用分析以评估维生素D受体基因型对维生素D反应的影响(3)。该试验已在ClinicalTrials.gov上注册为NCT00419068。结果:126例患者被纳入主要疗效分析(62例为介入治疗,64例为安慰剂治疗)。干预组中痰培养转化的中位时间为36.0天,而安慰剂组为43.5天(调整后的危险比1.39,95%CI 0.90-2.16; p = 0.14)。 TaqI基因型改变了补充维生素D对痰培养转化时间的影响(p(相互作用)= 0.03),仅在tt基因型患者中观察到了增强的反应(8.09,95%CI 1.36-48.01; p = 0.02)。 FokI基因型没有改变补充维生素D的效果(p(相互作用)= 0.85)。干预组56天的平均血清25-羟基维生素D浓度为101.4 nmol / L,而安慰剂组为22.8 nmol / L(95%CI,差异68.6-88.2; p <0.0001)。解释:在接受肺结核强化治疗的患者中,四剂2.5 mg维生素D(3)的使用增加了血清25-羟基维生素D的浓度。在整个研究人群中,维生素D不会显着影响痰培养转化的时间,但是它确实具有TaqI维生素D受体多态性tt基因型的参与者的痰培养转化。资金来源:英国肺基金会。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号